Benazepril HCl en es it fr

Benazepril HCl Brand names, Benazepril HCl Analogs

Benazepril HCl Brand Names Mixture

  • Lotensin HCT (Benazepril Hydrochloride + Hydrochlorothiazide)
  • Lotrel (Benazepril Hydrochloride + Amlodipine Besylate)

Benazepril HCl Chemical_Formula

C24H28N2O5

Benazepril HCl RX_link

http://www.rxlist.com/cgi/generic/benaz.htm

Benazepril HCl fda sheet

Benazepril_HCl FDA

Benazepril HCl msds (material safety sheet)

Benazepril_HCl MSDS

Benazepril HCl Synthesis Reference

U.S.pat.4,410,520(1983)

Benazepril HCl Molecular Weight

424.49 g/mol

Benazepril HCl Melting Point

148-149 oC

Benazepril HCl H2O Solubility

2.229 mg/L

Benazepril HCl State

Solid

Benazepril HCl LogP

3.217

Benazepril HCl Dosage Forms

Tablet (5 mg, 10 mg, 20 mg, 40 mg)

Benazepril HCl Indication

For the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.

Benazepril HCl Pharmacology

Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.

Benazepril HCl Absorption

Peak in plasma within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract.

Benazepril HCl side effects and Toxicity

Symptoms of overdose include swelling of face, mouth, hands, or feet, trouble in swallowing or breathing (sudden), hoarseness, fever and chills.

Benazepril HCl Patient Information

Pregnancy

Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

Angioedema

Angioedema, including laryngeal edema, can occur at any time with treatment with ACE inhibitors. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.

Symptomatic Hypotension

Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported to the prescribing physician. Patients should be told that if syncope occurs, Lotensin should be discontinued until the prescribing physician has been consulted.

All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

Hyperkalemia

Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.

Neutropenia

Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.

Benazepril HCl Organisms Affected

Humans and other mammals